Skin Adverse Events Linked to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Disproportionality Analysis Using FAERS and Drug–Gene Interaction Network Analyses

Background

While tyrosine kinase inhibitors (TKIs) targeting the epidermal growth factor receptor (EGFR) have improved outcomes for non-small cell lung cancer (NSCLC) patients, these inhibitors also cause skin adverse events (AEs). Moreover, real-world, data driven studies on EGFR-TKI-related AEs remain limited. In particular, the mechanisms underlying EGFR-TKI-induced skin AEs remain unclear.